CH, What is so disheartening is the reason for the unrelenting secretiveness and the extent to which it is necessary. Why is it necessary, other than for avoiding the issue of no actual good news? The FDA partial clinical hold was placed on PBT2 for Reach2HD. We have heard no reason why clinical trials have not gone ahead for AD, Parkinson's or any of the other applications in that "vast" pipeline. Is that now the recommendation of the FDA, or is it because of Prana's current financial state?
Has the FDA now formally placed an actual full clinical hold on all of the clioquinol derivatives or is that Prana's decision for various unknown reasons? It certainly appears to be a complete clinical hold with the pattern of no clinical trials = no approvals = little funding = no clinical trials = no earnings etc etc etc. The negative merry-go-round continues.
Prana has provided no explanation for not taking PBT2 for a Huntington's trial in Europe. Is there a possibility that application was actually made to the EMA but rejected because of the FDA's concerns?
The entire world knows of the clinical hold and very long period of Prana's inactivity. No wonder that they can't get on a productive path including the necessity of attracting collaborative partners to help them through the FDA process and with badly-needed financial backing lacking by institutions and funds.
PBT Price at posting:
12.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)